Giuseppe Leone: This Review by Offidani’s Group Compares Clinical Trials and Outlines Prospects
LABORATORY Professionals International reposted Giuseppe Leone’s post on LinkedIn:
“At major international conferences in 2024, important data emerged on new approaches capable of improving outcomes even in high-risk or very advanced disease. Upfront quadruplet combinations, including anti-CD38 monoclonal antibodies, have proven to be the best therapy in terms of depth of response and long-term efficacy in both transplant-eligible and ineligible patients. Despite the introduction of these therapies, high-risk multiple myeloma (MM) remains challenging to treat. This review by Offidani’s group compares clinical trials and outlines prospects.”
Title: Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES
Authors: Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Read more here.
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026